GlassScriptPhysician profile
Shahzaib Khan
NPI 1134741028
$2,730.38
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.52 · 2021: $49.38 · 2022: $770 · 2023: $1,333 · 2024: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $398.37 | 2022-2024 | Abilify Maintena, Nuedexta |
| Janssen Pharmaceuticals, INC | $382.60 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Indivior INC. | $363.77 | 2022-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $253.81 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $189.45 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Ironshore Pharmaceuticals INC. | $161.50 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $126.21 | 2022-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $122.86 | 2022-2023 | Ingrezza |
| Almatica Pharma LLC | $114.20 | 2021-2024 | Loreev Xr |
| Lundbeck LLC | $100.08 | 2021-2024 | Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $84.45 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $80.69 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $75.15 | 2021-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $69.83 | 2022-2023 | Fanapt, Hetlioz |
| Corium, LLC | $66.66 | 2022-2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.98 | 2023-2024 | |
| Biogen, INC. | $33.37 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.88 | 2020-2023 | Lifevest |
| Mirum Pharmaceuticals, INC. | $20.37 | 2024 | Livmarli |
| Tris Pharma INC | $14.15 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahzaib Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.